<DOC>
	<DOCNO>NCT00160602</DOCNO>
	<brief_summary>A 24 week study patient give study medication assess sign symptom rheumatoid arthritis . X-rays perform assess progress joint damage study .</brief_summary>
	<brief_title>A Study Liquid Certolizumab Pegol Additional Medication Methotrexate Treatment Signs Symptoms Rheumatoid Arthritis Prevention Joint Damage Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients must least 18 year old screening visit . Patients must diagnosis adultonset RA least six month duration longer fifteen year define 1987 American College Rheumatology classification criterion . Patients must active RA disease define : 9 tender joint Screening Baseline . 9 swollen joint Screening Baseline . fulfil 1 follow 2 criterion screen period : 30 mm/hour ESR ( Westergren ) , CRP &gt; 15 mg/L . Patients must receive treatment MTX ( without folic acid ) least 6 month prior Baseline visit . The dose MTX route administration must stable least 2 month prior baseline visit . The minimum stable dose MTX allow 10 mg weekly . Patients must willing complete Xray hand foot 24 week randomization even longer receive study treatment present study , provide withdrawn inform consent . Patients must diagnosis inflammatory arthritis ( e.g. , psoriatic arthritis ankylose spondylitis ) . Patients must secondary , noninflammatory type arthritis ( e.g . OA fibromyalgia ) Female patient breast feeding , pregnant , plan become pregnant trial three month follow last dose study drug . Patients history tuberculosis positive chest Xray tuberculosis positive Patients high risk infection ( e.g . leg ulcer , indwell urinary catheter persistent recurrent chest infection patient permanently bed ridden wheelchair bound ) . Patients know human immunodeficiency virus ( HIV ) infection . Patients active malignancy type history malignancy ( except basal cell carcinoma skin excise prior study start ) . Patients current recent history , determine Investigator , severe , progressive , and/or uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral disease would interfere patient 's participation trial . Patients history , suspect , demyelinate disease central nervous system ( e.g . multiple sclerosis optic neuritis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Certolizumab Pegol , Cimzia</keyword>
</DOC>